Agios's Thalassemia Launch Ships into a New Phase as the Pipeline Diversifies
Q2 revenue hits $44.7M, 442 cumulative prescriptions, and a November PDUFA for sickle cell—while the company recalibrates how it measures commercial success.
AGIO · Earnings Call · 2026-07-30
Commercial Transition: From Scripts to Revenue
Agios Pharmaceuticals is balancing a maturing launch with an expanding pipeline. In the second quarter, total net revenue reached $44.7 million, including $40.9 million in the U.S., and cumulative AQVESME prescriptions hit 442. But the more telling shift is the company's decision to retire the script-count metric after the third quarter, moving to revenue as the primary performance gauge. As Tsveta Milanova, Chief Commercial Officer, explained:
As the launch matures, prescriptions with completed start forms become a less informative measure of performance, whereas revenue increasingly reflects both new patient starts and persistence on therapy.
That shift is anchored in the time to treatment dynamics. The early launch was powered by highly motivated transfusion-dependent patients, but the company is now deliberately courting the broader non-transfusion-dependent (NTDT) population. Tsveta noted that as they penetrate the NTDT setting, treatment decisions take longer, and the average time to initiation will settle into the anticipated 10–12 week range. The launch is moving from a "bolus" phase to a steadier cadence.
The company is also refocusing its reporting. “We had in total 442 prescriptions from REMS-certified physicians for the first 2 quarters of the launch,” — Tsveta Milanova, Chief Commercial Officer · 2026-07-30 Tsveta told Alec Stranahan, but added that prescription growth and revenue growth will no longer correlate perfectly. The metric that matters going forward is net revenue, which will incorporate new starts, persistence, and gross-to-net dynamics. This pivot was anticipated. Back in February, the commercial team had already framed expectations carefully: “We are really encouraged by the early demand that we are seeing with Afesmi.” — Cecilia Jones, Chief Commercial Officer · 2026-02-12
Pipeline Deepens Beyond Mitapivat
Beyond the launch, Agios is intentionally diversifying its rare hematology portfolio. The in-licensing of cevidoplenib, a next-generation SYK inhibitor for ITP, adds a new mechanism and a new indication. “We are executing against multiple drivers of value creation, including the launch of AQVESME in thalassemia, the potential expansion of Mitapivat into sickle cell disease and a pipeline that continues to grow through both internal innovation and disciplined business development,” — Brian Goff, Chief Executive Officer · 2026-07-30 said CEO Brian Goff.
The most tangible catalyst is the sickle cell sNDA, now with a priority review and a PDUFA date of November 1. Management is downplaying the need for a REMS, citing the absence of hepatocellular injury in the sickle cell trials. Meanwhile, AG-236, the siRNA targeting TMPRSS6 for polycythemia vera, is advancing into a seamless Phase II/III program, with Phase II initiation planned for the second half.
The company's rare hematology focus is broadening, but the financial picture remains disciplined. Agios ended the quarter with approximately $1 billion in cash. Total revenue is inflecting: total revenue reached $21 million in Q1 2026, up 138% year-over-year, and the gross margin remains above 90%. However, R&D and SG&A expenses are climbing as the company prepares for the sickle cell launch, and operating losses persist.
Financial Flexibility and the Path Forward
The balance sheet gives Agios optionality. Management reiterated its 2026 outlook: $45–50 million from PK deficiency revenues in the U.S., and total operating expenses roughly flat excluding the $25 million upfront payment for cevidoplenib. That discipline is consistent with prior quarters. In April, Tsveta had cautioned against extrapolating the Q1 script run-rate: “I wouldn't take Q1 to be the run rate for upcoming quarters. But what I can tell you is that we still expect very strong demand and uptake as the team continues to execute very strongly and the reception from both patients and physicians on the AQVESME profile has been very, very positive.” — Tsveta Milanova, Chief Commercial Officer · 2026-04-29
That sentiment now extends to a more sophisticated understanding of the launch curve. As the company moves away from start form metrics, investors will need to rely on revenue and persistence data. The stock, however, has pulled back about 25% from its July peak, trading flat over the past three months. The market may be wrestling with the execution risk of a third indication and the launch into a more challenging payer mix (higher Medicaid).
Still, the company's strategic evolution is clear. With a growing commercial foundation, a near-term regulatory catalyst, and a pipeline that now spans multiple mechanisms, Agios is positioning itself as a multi-franchise rare disease player. As Brian Goff said, “We entered the second half of the year with a growing commercial foundation, a meaningful near-term regulatory catalyst and an increasingly diversified pipeline and the financial strength to execute on our strategy.” — Brian Goff, Chief Executive Officer · 2026-07-30
The upcoming months—between the thalassemia revenue maturation and the November PDUFA—will be pivotal. The company is effectively handing investors a new set of metrics, and the next few quarters will reveal whether the shift from scripts to revenue is a sign of strength or a concession to a slower-than-expected growth curve.